Literature DB >> 17713719

Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity - a [11C]DASB PET study.

M Reimold1, M N Smolka, A Zimmer, A Batra, A Knobel, C Solbach, A Mundt, H U Smoltczyk, D Goldman, K Mann, G Reischl, H-J Machulla, R Bares, A Heinz.   

Abstract

Reduced availability of brainstem serotonin transporters (5-HTT) has been observed in vivo in obsessive-compulsive disorder (OCD). However, results vary and may be influenced by competition with endogenous serotonin. Using positron emission tomography (PET) and [11C]DASB, a specific 5-HTT ligand that showed no competition with serotonin for 5-HTT binding in vitro, we tested the hypothesis that 5-HTT availability is reduced in OCD patients and correlated with OCD severity. METHODS. 5-HTT availability in the thalamus and the midbrain was measured in nine drug-free OCD patients and compared with 19 healthy controls, matched for the individual combination of 5-HTT genotype, gender and smoking status. OCD severity was assessed with the Yale-Brown obsessive compulsive scale (Y-BOCS). RESULTS. 5-HTT availability was significantly reduced in the thalamus and midbrain of OCD patients. Age and 5-HTT in the thalamus explained 83% of OCD severity in patients that were drug-free for at least 1 year. CONCLUSION. This PET study confirms a central role of the serotonergic system, particularly the thalamus in the pathogenesis of obsessive compulsive disorder.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17713719     DOI: 10.1007/s00702-007-0785-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  47 in total

Review 1.  Consensus nomenclature for in vivo imaging of reversibly binding radioligands.

Authors:  Robert B Innis; Vincent J Cunningham; Jacques Delforge; Masahiro Fujita; Albert Gjedde; Roger N Gunn; James Holden; Sylvain Houle; Sung-Cheng Huang; Masanori Ichise; Hidehiro Iida; Hiroshi Ito; Yuichi Kimura; Robert A Koeppe; Gitte M Knudsen; Juhani Knuuti; Adriaan A Lammertsma; Marc Laruelle; Jean Logan; Ralph Paul Maguire; Mark A Mintun; Evan D Morris; Ramin Parsey; Julie C Price; Mark Slifstein; Vesna Sossi; Tetsuya Suhara; John R Votaw; Dean F Wong; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2007-05-09       Impact factor: 6.200

2.  Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Authors:  Masanori Ichise; Jeih-San Liow; Jian-Qiang Lu; Akihiro Takano; Kendra Model; Hiroshi Toyama; Tetsuya Suhara; Kazutoshi Suzuki; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

3.  Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

Authors:  Xian-Zhang Hu; Robert H Lipsky; Guanshan Zhu; Longina A Akhtar; Julie Taubman; Benjamin D Greenberg; Ke Xu; Paul D Arnold; Margaret A Richter; James L Kennedy; Dennis L Murphy; David Goldman
Journal:  Am J Hum Genet       Date:  2006-03-28       Impact factor: 11.025

4.  Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Comparison of fluvoxamine and desipramine.

Authors:  W K Goodman; L H Price; P L Delgado; J Palumbo; J H Krystal; L M Nagy; S A Rasmussen; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1990-06

5.  An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk.

Authors:  Xianzhang Hu; Gabor Oroszi; Jeffrey Chun; Tom L Smith; David Goldman; Marc A Schuckit
Journal:  Alcohol Clin Exp Res       Date:  2005-01       Impact factor: 3.455

6.  Effects of reduced endogenous 5-HT on the in vivo binding of the serotonin transporter radioligand 11C-DASB in healthy humans.

Authors:  Peter S Talbot; W Gordon Frankle; Dah-Ren Hwang; Yiyun Huang; Raymond F Suckow; Mark Slifstein; Anissa Abi-Dargham; Marc Laruelle
Journal:  Synapse       Date:  2005-03-01       Impact factor: 2.562

7.  SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates.

Authors:  M Laruelle; R M Baldwin; R T Malison; Y Zea-Ponce; S S Zoghbi; M S al-Tikriti; E H Sybirska; R C Zimmermann; G Wisniewski; J L Neumeyer
Journal:  Synapse       Date:  1993-04       Impact factor: 2.562

Review 8.  Frontal-subcortical circuits and human behavior.

Authors:  J L Cummings
Journal:  Arch Neurol       Date:  1993-08

9.  [18F]FDG PET study in obsessive-compulsive disorder. A clinical/metabolic correlation study after treatment.

Authors:  D Perani; C Colombo; S Bressi; A Bonfanti; F Grassi; S Scarone; L Bellodi; E Smeraldi; F Fazio
Journal:  Br J Psychiatry       Date:  1995-02       Impact factor: 9.319

10.  Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study.

Authors:  M Reimold; A Batra; A Knobel; M N Smolka; A Zimmer; K Mann; C Solbach; G Reischl; F Schwärzler; G Gründer; H-J Machulla; R Bares; A Heinz
Journal:  Mol Psychiatry       Date:  2008-02-12       Impact factor: 15.992

View more
  21 in total

1.  Central serotonin transporter levels are associated with stress hormone response and anxiety.

Authors:  Matthias Reimold; Astrid Knobel; Michael A Rapp; Anil Batra; Klaus Wiedemann; Andreas Ströhle; Anke Zimmer; Peter Schönknecht; Michael N Smolka; Daniel R Weinberger; David Goldman; Hans-Jürgen Machulla; Roland Bares; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

Review 2.  Obsessive-compulsive disorder: Insights from animal models.

Authors:  Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter
Journal:  Neurosci Biobehav Rev       Date:  2016-05-07       Impact factor: 8.989

3.  Monoamine abnormalities in the SAPAP3 knockout model of obsessive-compulsive disorder-related behaviour.

Authors:  Jesse Wood; Zoe LaPalombara; Susanne E Ahmari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-03-19       Impact factor: 6.237

Review 4.  What have positron emission tomography and 'Zippy' told us about the neuropharmacology of drug addiction?

Authors:  Paul Cumming; Daniele Caprioli; Jeffrey W Dalley
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

5.  Brain regional α-[11C]methyl-L-tryptophan trapping in medication-free patients with obsessive-compulsive disorder.

Authors:  Alexandre Berney; Marco Leyton; Paul Gravel; Igor Sibon; Debbie Sookman; Pedro Rosa Neto; Mirko Diksic; Akio Nakai; Gilbert Pinard; Christo Todorov; Hidehiko Okazawa; Pierre Blier; Thomas Edward Nordahl; Chawki Benkelfat
Journal:  Arch Gen Psychiatry       Date:  2011-03-07

Review 6.  Peromyscus maniculatus bairdii as a naturalistic mammalian model of obsessive-compulsive disorder: current status and future challenges.

Authors:  De Wet Wolmarans; Isabella M Scheepers; Dan J Stein; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2017-12-06       Impact factor: 3.584

Review 7.  The neurocircuitry of fear, stress, and anxiety disorders.

Authors:  Lisa M Shin; Israel Liberzon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

Review 8.  Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD.

Authors:  Benjamin D Greenberg; Scott L Rauch; Suzanne N Haber
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

9.  The aggression and behavioral abnormalities associated with monoamine oxidase A deficiency are rescued by acute inhibition of serotonin reuptake.

Authors:  Sean C Godar; Marco Bortolato; M Paola Castelli; Alberto Casti; Angelo Casu; Kevin Chen; M Grazia Ennas; Simone Tambaro; Jean C Shih
Journal:  J Psychiatr Res       Date:  2014-05-15       Impact factor: 4.791

10.  Caloric restriction enhances fear extinction learning in mice.

Authors:  Megan C Riddle; Morgan C McKenna; Yone J Yoon; Siobhan S Pattwell; Patricia Mae G Santos; B J Casey; Charles E Glatt
Journal:  Neuropsychopharmacology       Date:  2013-01-03       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.